Chinese Expert Consensus on Management of Thrombocytopenia in Cancer Patients with Liver Injury (2022 Edition)

Committee of Neoplastic Supportive-care (CONS), China Anti-Cancer Association

doi:10.3971/j.issn.1000-8578.2023.23.0156

Cancer Research on Prevention and Treatment > 2023 > 50(3): 211-223. > DOI: 10.3971/j.issn.1000-8578.2023.23.0156

Committee of Neoplastic Supportive-care (CONS), China Anti-Cancer Association. Chinese Expert Consensus on Management of Thrombocytopenia in Cancer Patients with Liver Injury (2022 Edition)[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 211-223. DOI: 10.3971/j.issn.1000-8578.2023.23.0156

Citation:

PDF (2066 KB)

Chinese Expert Consensus on Management of Thrombocytopenia in Cancer Patients with Liver Injury (2022 Edition)

Committee of Neoplastic Supportive-care (CONS), China Anti-Cancer Association

More Information

Corresponding Author: YUAN Xianglin, E-mail: yuanxianglin@hust.edu.cn
Received Date: February 19, 2023
Revised Date: February 26, 2023
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Thrombocytopenia and liver injury are common and serious clinical problems in cancer patients. The etiology of thrombocytopenia in cancer patients with liver injury (TCLI) is complicated, which is common in liver injury and tumor treatment. The management of cancer therapy-induced thrombocytopenia has gradually become standardized, and the management of liver injury-associated thrombocytopenia is becoming clear with the approval and marketing of relevant drugs. However, the management of TCLI is still blank, and the superposition of thrombocytopenia and liver injury further increases the difficulty of cancer treatment. Therefore, the Committee of Neoplastic Supportive-care, China Anti-Cancer Association organizes experts to analyze and discuss relevant literatures to form a Chinese expert consensus on the management of thrombocytopenia in cancer patients with liver injury (2022 Edition) to guide clinical practice.
- Cancer,
- Liver disease,
- Liver injury,
- Thrombocytopenia,
- Expert consensus

FullText(HTML)

References (87)

References

[1]	全军重症医学专业委员会, 中华医学会检验医学分会. 中国成人重症患者血小板减少诊疗专家共识[J]. 解放军医学杂志, 2020, 45(5): 457-474. http://www.cnki.com.cn/Article/CJFDTotal-JFJY202005002.htm People's Liberation Army Professional Committee of Critical Care Medicine, CMA Chinese Society of Laboratory Medicine. Expert Consensus on the Diagnosis and Treatment of Thrombocytopenia in Adult Critical Care Patients in China[J]. Jiefangjun Yi Xue Za Zhi, 2020, 45(5): 457-474. . http://www.cnki.com.cn/Article/CJFDTotal-JFJY202005002.htm
[2]	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650): 924-926. doi: 10.1136/bmj.39489.470347.AD
[3]	Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71(1): 212-221. doi: 10.1016/j.jhep.2019.03.004
[4]	Gangireddy VG, Kanneganti PC, Sridhar S, et al. Management of thrombocytopenia in advanced liver disease[J]. Can J Gastroenterol Hepatol, 2014, 28(10): 558-564. doi: 10.1155/2014/532191
[5]	Maan R, de Kncgt RJ, Veldt BJ. Management of thrombocytopenia in chronic liver disease: focus on pharmacotherapeutic strategies[J]. Drugs, 2015, 75(17): 1981-1992. doi: 10.1007/s40265-015-0480-0
[6]	Yoshida M, Tateishi R, Hiroi S, et al. Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data[J]. Adv Ther, 2022, 39(2): 992-1003. doi: 10.1007/s12325-021-02008-x
[7]	Huang CE, Chang JJ, Wu YY, et al. Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection[J]. Biomed J, 2021, 45(5): 788-797.
[8]	Scharf RE. Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management[J]. J Clin Med, 2021, 10(7): 1530. doi: 10.3390/jcm10071530
[9]	Gallo P, Terracciani F, Di Pasquale G, et al. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures[J]. World J Gastroenterol, 2022, 28(30): 4061-4074. doi: 10.3748/wjg.v28.i30.4061
[10]	李尚书, 刘群, 黄丽雯. 慢性肝病血小板减少的原因[J]. 中国肝脏病杂志(电子版), 2021, 13(2): 24-28. doi: 10.3969/j.issn.1674-7380.2021.02.005 Li SS, Liu Q, Huang LW. Causes of Thrombocytopenia in Chronic Liver Disease[J]. Zhongguo Gan Zang Bing Za Zhi (Dian Zi Ban), 2021, 13(2): 24-28. doi: 10.3969/j.issn.1674-7380.2021.02.005
[11]	Pradella P, Bonetto S, Turchetto S, et al. Platelet production and destruction in liver cirrhosis[J]. J Hepatol, 2011, 54(5): 894-900. doi: 10.1016/j.jhep.2010.08.018
[12]	Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis[J]. Hepatology, 2003, 37(6): 1267-1276. doi: 10.1053/jhep.2003.50209
[13]	Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis[J]. Thromb Haemost, 2008, 99(6): 1019-1029. doi: 10.1160/TH08-01-0006
[14]	Shahidi M. Thrombosis and von Willebrand factor[J]. Adv Exp Med Biol, 2017, 906: 285-306.
[15]	Brown RS Jr. Current management of thrombocytopenia in chronic liver disease[J]. Gastroenterol Hepatol (N Y), 2019, 15(3): 155-157.
[16]	中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中华临床感染病杂志, 2014, 7(1): 4-12. doi: 10.3760/cma.j.issn.1674-2397.2014.01.002 Chinese Society of Infectious Diseases, Chinese Medical Association, Expert Committee for Prevention and Management of Liver Inflammation. Consensus statement by the expert committee for prevention and management of liver inflammation in China[J]. Zhonghua Lin Chuang Gan Ran Bing Za Zhi, 2014, 7(1): 4-12. doi: 10.3760/cma.j.issn.1674-2397.2014.01.002
[17]	中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 42-49. Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis (2021)[J]. Lin Chuang Gan Dan Bing Za Zhi, 2022, 38(1): 42-49.
[18]	王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 9-32. Wang GQ, Duan ZP, Wang FS, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition)[J]. Shi Yong Gan Zang Bing Za Zhi, 2020, 23(1): 9-32.
[19]	魏来, 段钟平, 王贵强. 丙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 33-52. Wei L, Duan ZP, Wang GQ. Guidelines for the Prevention and Treatment of Hepatitis C (2019 Edition)[J]. Shi Yong Gan Zang Bing Za Zhi, 2020, 23 (1): 33-52.
[20]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志, 2018, 26(3): 195-203. doi: 10.3760/cma.j.issn.1007-3418.2018.03.008 National Workshop on Fatty Liver and Alcoholic Liver Disease of CMA Chinese Society of Hepatology, CMDA Fatty Liver Expert Committee. Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease (2018 Update)[J]. Zhonghua Gan Zang Bing Za Zhi, 2018, 26(3): 195-203. doi: 10.3760/cma.j.issn.1007-3418.2018.03.008
[21]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 实用肝脏病杂志, 2018, 21(2): 170-176. doi: 10.3969/j.issn.1672-5069.2018.02.006 National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of Prevention and Treatment for Alcoholic Liver Disease (2018 Update)[J]. Shi Yong Gan Zang Bing Za Zhi, 2018, 21(2): 170-176. doi: 10.3969/j.issn.1672-5069.2018.02.006
[22]	Al-Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia[J]. Expert Rev Hematol, 2021, 14(5): 437-448. doi: 10.1080/17474086.2021.1924053
[23]	孙亚红, 黎莉, 侯明, 等. 恶性肿瘤非免疫性血小板减少患者血小板特异性抗体的研究[J]. 肿瘤研究与临床, 2005, 17(3): 167-169. doi: 10.3760/cma.j.issn.1006-9801.2005.03.009 Sun YH, Li L, Hou M, et al. Study on the Specific autoantibody in Nonimmune Thrombocytopenia in Malignant Tumor[J]. Zhong Liu Yan Jiu Yu Lin Chuang, 2005, 17(3): 167-169. doi: 10.3760/cma.j.issn.1006-9801.2005.03.009
[24]	王汉萍. 肝癌免疫检查点抑制剂治疗相关不良反应及处理[J]. 临床肝胆病杂志, 2022, 38(5): 985-991. doi: 10.3969/j.issn.1001-5256.2022.05.003 Wang HP. Adverse reactions associated with immune checkpoint inhibitors in treatment of liver cancer and related treatment measures[J]. Lin Chuang Gan Dan Bing Za Zhi, 2022, 38(5): 985-991. doi: 10.3969/j.issn.1001-5256.2022.05.003
[25]	中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(8): 617-623. Thrombosis and Hemostasis Group of CMA Chinese Society of Hematology. Chinese Guidelines on the Diagnosis and Treatment of adult Primary Immune Thrombocytopenia(version 2020)[J]. Zhonghua Xue Ye Xue Za Zhi, 2020, 41(8): 617-623.
[26]	中华医学会肿瘤学分会肿瘤支持康复治疗学组. 肿瘤治疗相关血小板减少症的临床管理专家共识[J]. 肿瘤, 2021, 41(12): 812-827. Tumor Support and Rehabilitation Therapy Group of CMA Chinese Society of Oncology. Consensus on Clinical Management of Cancer Therapy-related Thrombocytopenia[J]. Zhong Liu, 2021, 41(12): 812-827.
[27]	National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0[M]. Rockville: HHS U S A Department of Health and Human Services, 2017.
[28]	李清, 陈雷, 余晓红. 慢性肝病血小板减少症与原发免疫性血小板减少症的骨髓细胞形态的鉴别[J]. 中国实用医刊, 2022, 49(8): 10-12. Li Q, Chen L, Yu XH. Differentiation of Bone Marrow Cell Morphology of Thrombocytopenia in Chronic Liver Disease and Primary Immune Thrombocytopenia[J]. Zhongguo Shi Yong Yi Kan, 2022, 49(8): 10-12.
[29]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO) 肿瘤治疗所致血小板减少症诊疗指南2022[M]. 北京: 人民卫生出版社, 2022. Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Cancer Therapy-Induced Thrombocytopenia[M]. Beijing: People's Medical Publishing House, 2022.
[30]	Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets[J]. Hepatology, 2006, 44(2): 440-445. doi: 10.1002/hep.21266
[31]	Tripodi A, Primignani M, Chantarangkul V, et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion[J]. Liver Int, 2013, 33(3): 362-367. doi: 10.1111/liv.12038
[32]	Northup PG, Friedman LS, Kamath PS. AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review[J]. Clin Gastroenterol Hepatol, 2019, 17(4): 595-606. doi: 10.1016/j.cgh.2018.09.043
[33]	O'Shea RS, Davitkov P, Ko CW, et al. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis[J]. Gastroenterology, 2021, 161(5): 1615-1627. e1. doi: 10.1053/j.gastro.2021.08.015
[34]	Schiffer CA, Bohlke K, Delaney M, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update[J]. J Clin Oncol, 2018, 36(3): 283-299. doi: 10.1200/JCO.2017.76.1734
[35]	Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies[J]. Haematologica, 2022, 107(6): 1243-1263. doi: 10.3324/haematol.2021.279512
[36]	Yang G, Huang R, Yang S, et al. Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers[J]. Br J Clin Pharmacol, 2020, 86(8): 1528-1536. doi: 10.1111/bcp.14259
[37]	Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia[J]. Gastroenterology, 2018, 155(3): 705-718. doi: 10.1053/j.gastro.2018.05.025
[38]	Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia[J]. N Engl J Med, 2012, 367(8): 716-724. doi: 10.1056/NEJMoa1110709
[39]	Moussa MM, Mowafy N. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28(2): 335-341. doi: 10.1111/j.1440-1746.2012.07246.x
[40]	Lindquist I, Olson SR, Li A, et al. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis[J]. Platelets, 2022, 33(1): 66-72. doi: 10.1080/09537104.2020.1859102
[41]	Kuter DJ. Milestones in understanding platelet production: a historical overview[J]. Br J Haematol, 2014, 165(2): 248-258. doi: 10.1111/bjh.12781
[42]	张静, 周新民. 应用重组人血小板生成素减少肝硬化患者术前血小板输注疗效初步研究[J]. 实用肝脏病杂志, 2020, 23(4): 552-555. doi: 10.3969/j.issn.1672-5069.2020.04.025 Zhang J, Zhou XM. Administration of recombinant human thrombopoietin before operation in patients with liver cirrhosis and hepatocellular carcinoma and thrombocytopenia[J]. Shi Yong Gan Zang Bing Za Zhi, 2020, 23(4): 552-555. doi: 10.3969/j.issn.1672-5069.2020.04.025
[43]	Feng R, Liu Y, Zhu XL, et al. Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study[J]. J Viral Hepat, 2022, 29(5): 306-316. doi: 10.1111/jvh.13655
[44]	Inc P. NEUMEGA Instrument[EB/OL]. https://www.pfizer.com/products/product-de-tail/neumega.
[45]	齐鲁制药有限公司. 注射用重组人白介素11说明书[EB/OL]. https://www.qilu-pharma.com/products_details/975814351594020864.html. Qilu Pharmaceutical Co., Ltd. Package Insert for Recombinant Human Interleukin 11 for Injection[EB/OL]. https://www.qilu-pharma.com/products_details/975814351594020864.html.
[46]	刘保文, 向慧玲, 梁静, 等. 重组人白介素-11及重组人血小板生成素在治疗肝硬化脾功能亢进所致血小板减少的疗效对比[J]. 世界华人消化杂志, 2016, 24(34): 4608-4614. http://www.cnki.com.cn/Article/CJFDTotal-XXHB201634020.htm Liu BW, Xiang HL, Liang J, et al. Comparison of the Efficacy of Recombinant Human Interleukin-11 and recombinant Human Thrombopoietin in the Treating Thrombocytopenia with Hypersplenism in cirrhotic patients[J]. Shi Jie Hua Ren Xiao Hua Za Zhi, 2016, 24(34): 4608-4614. http://www.cnki.com.cn/Article/CJFDTotal-XXHB201634020.htm
[47]	钱建丹, 姚甜甜, 王艳, 等. 慢性肝病相关血小板减少症管理策略[J]. 中华肝脏病杂志, 2021, 29(9): 896-899. Qian JD, Yao TT, Wang Y, et al. Management Strategies for Chronic Liver Disease-related Thrombocytopenia[J]. Zhonghua Gan Zang Bing Za Zhi, 2021, 29(9): 896-899.
[48]	Ogata T, Okuda K, Sato T, et al. Long-term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia[J]. Kurume Med J, 2013, 60(2): 37-45. doi: 10.2739/kurumemedj.MS62010
[49]	Kim NH, Kim HJ, Cho YK, et al. Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization[J]. J Korean Med Sci, 2019, 34(30): e208. doi: 10.3346/jkms.2019.34.e208
[50]	Feng K, Ma K, Liu Q, et al. Randomized clinical trial of splenic radiofrequency ablation versus splenectomy for severe hypersplenism[J]. Br J Surg, 2011, 98(3): 354-361. doi: 10.1002/bjs.7367
[51]	Shi XB, Feng JK, Wang JH, et al. Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9(8): 641. doi: 10.21037/atm-20-6748
[52]	Wu Y, Li H, Zhang T, et al. Splanchnic Vein Thrombosis in Liver Cirrhosis After Splenectomy or Splenic Artery Embolization: A Systematic Review and Meta-Analysis[J]. Adv Ther, 2021, 38(4): 1904-1930. doi: 10.1007/s12325-021-01652-7
[53]	Wang Q, Dang T, Meng X, et al. Is concomitant splenectomy necessary in radical gastric cancer surgery? A systematic review and meta-analysis[J]. Asia Pac J Clin Oncol, 2019, 15(2): e28-e35. doi: 10.1111/ajco.13052
[54]	王建雄, 魏丰贤, 谢文强, 等. 脾切除对肝硬化门静脉高压脾功能亢进患者影响的研究进展[J]. 中国普通外科杂志, 2022, 31(1): 123-131. Wang JX, Wei FX, Xie WQ, et al. Recent understandings of Splenectomy for Hypersplenism in Patients with cirrhotic Portal Hypertension[J]. Zhongguo Pu Tong Wai Ke Za Zhi, 2022, 31 (1): 123-131.
[55]	曹珊珊, 关月, 张筱芳, 等. 血小板生成素受体激动剂致不良反应的文献分析[J]. 中国药物应用与监测, 2022, 19(1): 34-38. Cao SS, Guan Y, Zhang XF, et al. Literature Analysis of Adverse Drug Reaction induced by Thrombopoietin Receptor Agonists[J]. Zhongguo Yao Wu Ying Yong Yu Jian Ce, 2022, 19(1): 34-38.
[56]	Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later[J]. Haematologica, 2019, 104(6): 1112-1123. doi: 10.3324/haematol.2018.212845
[57]	Hermann E, Ferdjallah A. Eltrombopag-induced Metabolic Acidosis and Hepatic Encephalopathy in Pediatric ITP[J]. J Pediatr Hematol Oncol, 2022, 44(2): e453-e455. doi: 10.1097/MPH.0000000000002300
[58]	Novartis Pharma Schwei AG. Instructions for Eltrombopag Olamine Tablets[EB/OL]. [2017-12-28]. https://zy.yaozh.com/instruct/sms20200619/2020060202.pdf.
[59]	徐薇薇, 杨磊, 葛建娟, 等. rhIL-11及rhTPO用于化疗所致的血小板减少症的疗效及安全性对比[J]. 系统医学, 2016, 1(12): 121-123. Xu WW, Yang L, Ge JJ, et al. Comparison of Efficacy and Safety of rhIL-11 and rhTPO in the treatment of Thrombocytopenia caused by chemotherapy[J]. Xi Tong Yi Xue, 2016, 1(12): 121-123.
[60]	喻杰, 戴晓芳, 刘莉, 等. rhTPO和IL-11治疗NSCLC化疗后血小板减少症的临床观察[J]. 中华肿瘤防治杂志, 2009, 16(5): 374-376. http://www.cnki.com.cn/Article/CJFDTotal-QLZL200905019.htm Yu J, Dai XF, Liu L, et al. Clinical studies of recombinant human thrombopoietin in treatment of gemzar and cisplatin-induced thrombocytopenia in patients with non-small cell lung cancer[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2009, 16(5): 374-376. http://www.cnki.com.cn/Article/CJFDTotal-QLZL200905019.htm
[61]	侯明, 李曼, 靳征. 重组人血小板生成素注射液上市后不良反应监测研究[J]. 中国新药与临床杂志, 2015, 34(8): 642-646. http://www.cnki.com.cn/Article/CJFDTotal-XYYL201508018.htm Hou M, Li M, Jin Z, et al. Post-marketing study of recombinant human thrombopoietin injection for adverse drug reaction monitoring[J]. Zhongguo Xin Yao Yu Lin Chuang Za Zhi, 2015, 34(8): 642-646. http://www.cnki.com.cn/Article/CJFDTotal-XYYL201508018.htm
[62]	戴晓芳, 喻杰, 刘莉, 等. 重组人血小板生成素治疗化疗相关血小板减少的临床价值[J]. 中华肿瘤杂志, 2008, 30(8): 623-625. Dai XF, Yu J, Liu L, et al. Value of recombinant human thrombopoietin in the treatmeat of chemotherapy-induced thrombocytopenia in patients with solid tumor[J]. Zhonghua Zhong Liu Za Zhi, 2008, 30(8): 623-625.
[63]	中国临床肿瘤学会抗淋巴瘤联盟, 中国抗癌协会癌症康复与姑息治疗专业委员会, 中华医学会血波学分会. 重组人白介素-11治疗血小板减少症临床应用中国专家共识(2018年版)[J]. 临床肿瘤学杂志, 2018, 23(3): 260-266. http://www.cnki.com.cn/Article/CJFDTotal-LCZL201803014.htm CSCO Anti-Lymphoma Alliance, CACA Committee of Cancer Rehabilitation and Palliative Care, Haematology Branch of Chinese Medical Association. Chinese Expert Consensus on Clinical Application of Recombinant Human Interleukin-11 in the Treatment of Thrombocytopenia (2018 Edition)[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2018, 23(3): 260-266. http://www.cnki.com.cn/Article/CJFDTotal-LCZL201803014.htm
[64]	Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther, 2010, 31(3): 366-374.
[65]	Chen H, Trilok G, Wang F, et al. A single hospital study on portal vein thrombosis in cirrhotic patients-clinical characteristics & risk factors[J]. Indian J Med Res, 2014, 139(2): 260-266.
[66]	Font C, Farrús B, Vidal L, et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients[J]. Ann Oncol, 2011, 22(9): 2101-2106.
[67]	中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. Hepatobiliary Disease Study Group of CMA Chinese Society of Gastroenterology. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. Lin Chuang Gan Dan Bing Za Zhi, 2020, 36(12): 2667-2674.
[68]	Falanga A, Leader A, Ambaglio C, et al. EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer[J]. Hemasphere, 2022, 6(8): e750.
[69]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)肿瘤患者静脉血栓防治指南2020[M]. 北京: 人民卫生出版社, 2020. Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Prevention and Treatment of Venous Thrombosis in Cancer Patients[M]. Beijing: People's Medical Publishing House, 2020.
[70]	Shen T, Liu Y, Shang J, et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11.
[71]	Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer[J]. Ann Oncol, 2004, 15(3): 460-466.
[72]	何福亮, 马琳, 李悦榕, 等. 非肝硬化性门脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4. He FL, Ma L, Li YR, et al. Non-cirrhotic portal hypertension: the highlight of its diagnosis[J]. Shi Yong Gan Zang Bing Za Zhi, 2022, 25(1): 1-4.
[73]	de Lédinghen V, Villate A, Robin M, et al. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4): 480-485.
[74]	赵爽, 赖荣陶, 谢青. 肝细胞癌免疫检查点抑制剂治疗相关毒性的诊断和临床管理[J]. 肝脏, 2020, 25(5): 451-455. http://www.cnki.com.cn/Article/CJFDTotal-ZUAN202005003.htm Zhao S, Lai RT, Xie Q. Diagnosis and Clinical Management of Treatment-Related Toxicity with Checkpoint Inhibitors in Hepatocellular Carcinoma[J]. Gan Zang, 2020, 25(5): 451-455. http://www.cnki.com.cn/Article/CJFDTotal-ZUAN202005003.htm
[75]	Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. LiveTox: Clinical and Research Information on Drug-Induced Liver Injury[EB/OL]. [2017-6-1]. https://www.ncbi.nlm.nih.gov/books/NBK547897/.
[76]	McDonald GB, Freston JW, Boyer JL, et al. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin)[J]. Hepatology, 2019, 69(2): 831-844.
[77]	江林宫, 孟鸿宇, 张火俊. 放射性肝损伤的研究进展[J]. 世界华人消化杂志, 2017, 25(20): 1811-1818. Jiang LG, Meng HY, Zhang HJ. Advances in research of radiation-induced liver damage[J]. Shi Jie Hua Ren Xiao Hua Za Zhi, 2017, 25(20): 1811-1818.
[78]	Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice[J]. BMC Cancer, 2019, 19(1): 151.
[79]	Crist M, Hansen E, Chablani L, et al. Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma[J]. Crit Rev Oncol Hematol, 2017, 120: 151-162.
[80]	中国抗癌协会妇科肿瘤专业委员会. PARP抑制剂不良反应管理的中国专家共识(2021年版)[J]. 中国实用妇科与产科杂志, 2021, 37(11): 1119-1130. http://www.cnki.com.cn/Article/CJFDTotal-ZGSF202111011.htm CACA Professional Committee of Gynecological Oncology. Chinese Expert Consensus on ADR Management of PARP Inhibitors (2021 Edition)[J]. Zhongguo Shi Yong Fu Ke Yu Chan Ke Za Zhi, 2021, 37(11): 1119-1130. http://www.cnki.com.cn/Article/CJFDTotal-ZGSF202111011.htm
[81]	Haddad TC, Zhao S, Li M, et al. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival[J]. Cancer Immunol Immunother, 2022, 71(5): 1157-1165.
[82]	傅青春. 药物性肝损伤诊断的因果评分系统[J]. 实用肝脏病杂志, 2014, 17(6): 569-571. Fu QC. Scoring system for diagnosis of drug-induced liver injuries[J]. Shi Yong Gan Zang Bing Za Zhi, 2014, 17(6): 569-571.
[83]	中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 药物性肝损伤基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19(10): 868-875. Chinese Medical Association, Chinese Medical Association Publishing House, Chinese Society Of Gastroenterology, et al. Guideline for primary care of drug-induced liver injury (2019)[J]. Zhonghua Quan Ke Yi Shi Za Zhi, 2020, 19(10): 868-875.
[84]	Bencardino K, Mauri G, Amatu A, et al. Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study[J]. Clin Colorectal Cancer, 2016, 15(3): 213-221.
[85]	Jácome AA, Ohinata A, Mahvash A, et al. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism[J]. Clin Colorectal Cancer, 2020, 19(4): e189-e199.
[86]	Overman MJ, Ferrarotto R, Raghav K, et al. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia[J]. J Natl Cancer Inst, 2018, 110(8): 888-894.
[87]	Qdaisat A, Yeung SJ, Rojas Hernandez CH, et al. Characteristics and Outcomes of Intracranial Hemorrhage in Cancer Patients Visiting the Emergency Department[J]. J Clin Med, 2022, 11(3): 643.

Cited By

Cited by

Periodical cited type(5)

1.	石宛鑫，闫慧文，于莉华，解宇晴，商子梦，蔡雪，梁羽玲，杨志云. 从益气养阴解毒法论治肝癌相关血小板减少症. 中西医结合肝病杂志. 2025(02): 226-229 .
2.	段秀芳，唐胜军，苑馨. 海曲泊帕治疗实体瘤化疗所致血小板减少症的效果分析. 系统医学. 2024(15): 166-168+176 .
3.	索凡替尼临床合理用药中国多学科专家共识编审小组. 索凡替尼临床合理用药中国多学科专家共识(2024版). 中华肿瘤杂志. 2024(10): 930-939 .
4.	周天琦，吴楠，白兆石，赵敏，张倩，季花，徐思露，魏继福. DRG付费下乳腺癌患者化疗致骨髓抑制及肝损伤治疗方案药物经济学评价. 中国医院药学杂志. 2024(22): 2633-2639 .
5.	黄远颖，杨秋敏，沈丽君，张湘兰，司徒健瑜，李孔扬. 小剂量泼尼松联合艾曲泊帕在成人慢性原发免疫性血小板减少症治疗中的应用研究. 中国医药科学. 2023(22): 94-97 .

Other cited types(3)

Get Citation

PDF

XML

Article views (3072) PDF downloads (1578) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Chinese Expert Consensus on Management of Thrombocytopenia in Cancer Patients with Liver Injury (2022 Edition)